SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as news circulates about the departure of a key FDA official, which the community believes removes a significant hurdle and could accelerate the approval path for their Duchenne Muscular Dystrophy (DMD) therapy, Deramiocel; this development, combined with upcoming Phase 3 data presentations, is intensifying short squeeze and buyout speculation.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending amid widespread speculation and fervent debate among investors regarding its potential inclusion in the S&P 500. While many anticipate a significant price movement based on the decision, others express frustration over past dilutions and current market volatility, yet maintain confidence in the company's long-term growth and recent insider buying.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is surging as a key FDA official's departure and reports of a less invasive trial design for its Huntington's gene therapy ignite community hopes for accelerated approval, triggering a significant short squeeze after a week of regulatory setbacks.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. (BNAI) is trending after completing an AI licensing partnership in Africa, which, combined with its low float and extremely high cost-to-borrow, is fueling intense short squeeze speculation among traders. The community is actively discussing strong buy-side pressure and the stock's resilience amidst a broader red market, with many holding for significant upside.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings (LITE) is trending amid its S&P 500 inclusion and a significant strategic investment from NVIDIA, solidifying its critical position in AI infrastructure expansion. The community is actively discussing whether its high valuation is justified by its role in supplying advanced optical components, particularly in light of industry perspectives on optical versus copper solutions for data center connectivity.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as the anticipated departure of a key FDA official fuels community speculation for a significantly softened regulatory landscape for gene therapies, with many expecting SRPT to follow recent rallies in comparable biotechs ahead of upcoming pivotal DM1 and FSHD data readouts.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

With upcoming clinical data readouts and potential international approvals for its personalized TIL therapy, Iovance Biotherapeutics is showing exceptional relative strength in a weak market, sparking community speculation of a significant short squeeze and potential buyout.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is surging as escalating conflict with Iran significantly disrupts oil traffic through the vital Strait of Hormuz, driving the biggest weekly crude gains in decades. The community is actively debating whether this is a genuine physical supply squeeze or fear-driven, with many expecting oil to climb well past $100 as regional producers face storage limits.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending as its fortified balance sheet, recent defense contract wins, U.S. Army qualification, and a new CEO compensation plan tied to aggressive valuation milestones spark intense community debate, balancing optimism for its critical role in aerospace and defense against concerns over institutional exits, high short interest, and potential dilution.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. It also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment offers products and services sold for applications within the data center, communication networks, and commercial and industrial markets in North America and Latin America. The Asia Pacific segment includes products and services sold for applications within the data center, communication networks, and commercial or industrial markets throughout Greater China, Australia and New Zealand, Southeast Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Columbus, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv Holdings Co. (VRT) is a major talking point among investors after its announcement to join the S&P 500 index on 3/23, leading to widespread discussion around anticipated 'inclusion play' gains and the implications of forced buying by index funds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Needham & Company LLC Lowers CorMedix (NASDAQ:CRMD) Price Target to $14.00

Needham & Company LLC dropped their target price on shares of CorMedix from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday...

CorMedix Q4 Earnings Call Highlights

CorMedix (NASDAQ:CRMD) executives said 2025 was a transformational year, highlighted by DefenCath reaching peak sales of just under $260 million, the acquisition of Melinta Therapeutics, and the...

CorMedix (NASDAQ:CRMD) Issues Earnings Results, Misses Estimates By $0.70 EPS

CorMedix (NASDAQ:CRMD - Get Free Report) posted its quarterly earnings results on Thursday. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.86 by ($0.70...

<ul class="summary-bullets"><li>CorMedix’s Q4 revenue included $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio.</li><li>Total operating expenses for Q4 rose to $48.2 million, up 181% year-on-year.</li><li>CorMedix ended 2025 with $148.5 million in cash, cash equivalents, and short-term investments.</li></ul>CorMedix Inc. (CRMD) stock gained attention on Thursday, after the company announced its fourth-quarter (Q4) and full-year financial results for 2025, reporting a 312% year-on-year (YoY) jump in revenue.&nbsp;The company reported Q4 revenue of $128.6 million and an earnings per share (EPS) of $0.16. Though CorMedix’s revenue surpassed analysts’ consensus estimate of $127 million, EPS came in way below the estimated $0.82, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2><a href="https://stocktwits.com/symbol/CRMD">CorMedix stock</a> traded over 11% lower on Thursday morning. However, on Stocktwits, retail sentiment around the stock flipped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘high’ from ‘low’ in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_05_092009_png_aaa43e3104.webp" alt="CRMD’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Mar. 5, 2026 | Source: Stocktwits" width="930" height="102"><figcaption>CRMD’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Mar. 5, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user said they are going long on the stock and hope to keep it until it climbs back to double digits.<stembedurl>https://stocktwits.com/JamesTiberius/message/646666139</stembedurl><h2 class="st-heading-2">Revenue Growth Driven by DefenCath and Melinta Acquisition</h2>CorMedix’s Q4 revenue included $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio. The Melinta revenue reflects the company’s first full quarter of contribution since its August 2025 acquisition.&nbsp;Total operating expenses for Q4 rose to $48.2 million, up 181% YoY. The expense increase primarily stems from the Melinta acquisition and includes $4.1 million in one-time costs, such as severance and integration expenses.&nbsp;<blockquote>“I am proud of the company’s progress over the past year as we have accelerated the expansion of patient access for DefenCath, completed our acquisition and integration of Melinta, and saw progress in our two ongoing Phase 3 clinical programs for Rezzayo prophylaxis and DefenCath in TPN.”-Joe Todisco, Chairman and CEO, CorMedix&nbsp;</blockquote>CorMedix ended 2025 with $148.5 million in cash, cash equivalents, and short-term investments, excluding restricted cash.CRMD stock has declined by over 37% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/help-stock-tanks-despite-strong-phase-2-results-for-anxiety-treatment-retail-buys-the-dip-ignoring-market-s-pessimism/cZdQHEpRI3O">HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Did CRMD Stock Tumble Over 11% Today?

The company reported mixed Q4 results with a revenue of $128.6 million and earnings per share of $0.16. 

Equity

CorMedix (CRMD) Lags Q4 Earnings Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of -29.07% and +1.03%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Cormedix Earnings Review: Q4 Summary

Royce & Associates LP Buys New Stake in CorMedix Inc $CRMD

Royce & Associates LP purchased a new stake in CorMedix Inc (NASDAQ:CRMD - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission...

CorMedix (CRMD) Projected to Post Quarterly Earnings on Thursday

CorMedix (NASDAQ:CRMD) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 5. (View Earnings Report at...

ANI Pharmaceuticals (ANIP) Surpasses Q4 Earnings and Revenue Estimates

ANI (ANIP) delivered earnings and revenue surprises of +17.32% and +6.04%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates

Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -166.67% and +0.23%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

$CRMD Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.18 down -18.18% YoY
• Reported revenue of $128.62M up 312.10% YoY
• CorMedix reiterates its 2026 guidance, projecting net revenue between $300M and $320M and adjusted EBITDA between $100M and $125M, reflecting its strategic outlook.

Stocktwits

CorMedix Inc

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of $0.18 down -18.18% YoY
• Reported revenue of $128.62M up 312.10% YoY
• CorMedix reiterates its 2026 guidance, projecting net revenue between $300M and $320M and adjusted EBITDA between $100M and $125M, reflecting its strategic outlook.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CRMD
CorMedix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRMD News

CRMDCorMedix Inc